BeiGene’s BTK Inhibitor was successfully launched in Ethiopia for CLL patients at Black Lion Hospital
John V. Oyler, Founder, Chairman & CEO at BeiGene, shared a post on LinkedIn:
“This week, I received an inspiring message from the The Max Foundation, highlighting a pivotal milestone for BeiGene. Our BTK Inhibitor was successfully launched in Ethiopia for CLL patients at Black Lion Hospital.
The message from the doctor on the ground conveyed the profound impact: patients are now filled with excitement and hope, while the hematology team is both motivated and relieved to have access to a first-line therapy that would have been unattainable for decades.
At BeiGene, we are committed to putting patients at the heart of everything we do. Their courage and resilience inspire us daily, driving our relentless pursuit to expand access to life-changing therapies worldwide.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023